Cardiol Therapeutics Inc
CRDL
查看详细走势图
0.995USD
+0.035+3.63%
收盘 02/06, 16:00（美东）报价延迟15分钟
87.00M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+3.63%
5天
+4.64%
1月
-0.52%
6月
-7.03%
今年开始到现在
+4.30%
1年
-31.39%
查看详细走势图
TradingKey Cardiol Therapeutics Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Cardiol Therapeutics Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名138/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价7.33。中期看，股价处于平稳状态。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Cardiol Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Cardiol Therapeutics Inc亮点
亮点风险
Cardiol Therapeutics Inc. is a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The Company is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.
估值合理
公司最新PE估值-3.33，处于3年历史合理位
机构加仓
最新机构持股11.26M股，环比增加18.17%
活跃度增加
近期活跃度增加，过去20天平均换手率2.20
分析师目标
根据
3
位分析师
买入
评级
7.333
目标均价
+663.89%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Cardiol Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Cardiol Therapeutics Inc简介
Cardiol Therapeutics Inc. is a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The Company is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.
公司代码CRDL
公司Cardiol Therapeutics Inc
CEOElsley (David)
网址https://www.cardiolrx.com/
相关品种
